NEW YORK (GenomeWeb News) – Quest Diagnostics today reported that its second-quarter revenues declined 3 percent year over year, as the diagnostics information services firm missed Wall Street estimates on the top and bottom line.

Quest had revenues of $1.82 billion for the three months ended June 30, compared to $1.88 billion for Q2 2012. It fell short of the consensus analysts' estimate of $1.84 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.

Cancer clinical trial patients settle with Anil Potti and Duke University.

A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.

Two Johns Hopkins researchers discuss the need for evidence-based data analysis.